Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7256 USD | -4.65% | -10.43% | +27.30% |
07:05pm | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
May. 14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.30% | 29.89M | |
+63.77% | 62.59B | |
-2.06% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.32% | 26.21B | |
-21.67% | 19.09B | |
+3.67% | 13.08B | |
+25.40% | 12.26B | |
+27.56% | 12.05B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Oppenheimer Adjusts Viracta Therapeutics Price Target to $16 From $14, Maintains Outperform Rating